These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 19053774

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.
    J Med Chem; 2007 Feb 22; 50(4):835-47. PubMed ID: 17300166
    [Abstract] [Full Text] [Related]

  • 4. Identification of novel selective V2 receptor non-peptide agonists.
    Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F.
    Biochem Pharmacol; 2008 Oct 30; 76(9):1134-41. PubMed ID: 18761325
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists.
    Paliwal S, Reichard GA, Shah S, Wrobleski ML, Wang C, Stengone C, Tsui HC, Xiao D, Duffy RA, Lachowicz JE, Nomeir AA, Varty GB, Shih NY.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4168-71. PubMed ID: 18547807
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production.
    Miyazaki H, Ogiku T, Sai H, Ohmizu H, Murakami J, Ohtani A.
    Bioorg Med Chem Lett; 2008 Dec 15; 18(24):6419-22. PubMed ID: 18993062
    [Abstract] [Full Text] [Related]

  • 9. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
    Tsukamoto I, Koshio H, Akamatsu S, Kuramochi T, Saitoh C, Yatsu T, Yanai-Inamura H, Kitada C, Yamamoto E, Sakamoto S, Tsukamoto S.
    Bioorg Med Chem; 2008 Nov 01; 16(21):9524-35. PubMed ID: 18835174
    [Abstract] [Full Text] [Related]

  • 10. Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
    Kondo K, Ogawa H, Shinohara T, Kurimura M, Tanada Y, Kan K, Yamashita H, Nakamura S, Hirano T, Yamamura Y, Mori T, Tominaga M, Itai A.
    J Med Chem; 2000 Nov 16; 43(23):4388-97. PubMed ID: 11087564
    [Abstract] [Full Text] [Related]

  • 11. The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.
    Westaway SM, Brown SL, Conway E, Heightman TD, Johnson CN, Lapsley K, Macdonald GJ, MacPherson DT, Mitchell DJ, Myatt JW, Seal JT, Stanway SJ, Stemp G, Thompson M, Celestini P, Colombo A, Consonni A, Gagliardi S, Riccaboni M, Ronzoni S, Briggs MA, Matthews KL, Stevens AJ, Bolton VJ, Boyfield I, Jarvie EM, Stratton SC, Sanger GJ.
    Bioorg Med Chem Lett; 2008 Dec 15; 18(24):6429-36. PubMed ID: 19006669
    [Abstract] [Full Text] [Related]

  • 12. Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.
    Matthews JM, Hoekstra WJ, Dyatkin AB, Hecker LR, Hlasta DJ, Poulter BL, Andrade-Gordon P, de Garavilla L, Demarest KT, Ericson E, Gunnet JW, Hageman W, Look R, Moore JB, Reynolds CH, Maryanoff BE.
    Bioorg Med Chem Lett; 2004 Jun 07; 14(11):2747-52. PubMed ID: 15125926
    [Abstract] [Full Text] [Related]

  • 13. Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists.
    Wiśniewski K, Qi S, Kraus J, Ly B, Srinivasan K, Tariga H, Croston G, La E, Wiśniewska H, Ortiz C, Laporte R, Rivière PJ, Neyer G, Hargrove DM, Schteingart CD.
    J Med Chem; 2019 May 23; 62(10):4991-5005. PubMed ID: 31022340
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aryl sulphonyl amides as potent agonists of the growth hormone secretagogue (ghrelin) receptor.
    Witherington J, Abberley L, Bellenie BR, Boatman R, Collis K, Dean DK, Gaiba A, King NP, Shuker N, Steadman JG, Takle AK, Sanger G, Butler S, McKay F, Muir A, Winborn K, Ward RW, Heightman TD.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):684-7. PubMed ID: 19128969
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Identification of small molecule agonists of the motilin receptor.
    Heightman TD, Conway E, Corbett DF, Macdonald GJ, Stemp G, Westaway SM, Celestini P, Gagliardi S, Riccaboni M, Ronzoni S, Vaidya K, Butler S, McKay F, Muir A, Powney B, Winborn K, Wise A, Jarvie EM, Sanger GJ.
    Bioorg Med Chem Lett; 2008 Dec 15; 18(24):6423-8. PubMed ID: 18980843
    [Abstract] [Full Text] [Related]

  • 18. The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease.
    Petersen MB.
    Basic Clin Pharmacol Toxicol; 2006 Aug 15; 99(2):96-103. PubMed ID: 16918709
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms.
    Andrés M, Peña A, Derick S, Raufaste D, Trojnar J, Wisniewski K, Trueba M, Serradeil-Le Gal C, Guillon G.
    Eur J Pharmacol; 2004 Oct 06; 501(1-3):59-69. PubMed ID: 15464063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.